198 results about "Pet imaging" patented technology

The present application provides a method for preparing a liquid composition containing Compound I, which comprises a step of purifying a crude product containing Compound I by high performance liquid chromatography, and its use in myocardial perfusion PET imaging, wherein the mobile phase used in the purification step by high performance liquid chromatography contains ethanol and water. By optimizing the process parameters and process flow, it can be applied to large-scale batch activity production and meet the needs of automation. The resulting myocardial perfusion PET contrast agent has high radiochemical purity, high activity concentration, good product stability, and high and stable yield or output.

The invention relates to a carbonic anhydrase IX targeted molecular probe and application thereof, and belongs to the technical field of nuclear medicine. The invention provides carbonic anhydrase IX targeted molecular probes 18F-SAZ and 18F-DAZ, and the two molecular probes have the following advantages: firstly, the specificity is strong, and the molecular probes can be selectively taken in a CAIX positive tumor part so as to better distinguish carbonic anhydrase IX negative and positive tumors; secondly, the compound can quickly reach a carbonic anhydrase IX positive tumor, a better imaging effect can be obtained within 30 minutes, and the compound has better retention property; and thirdly, the in-vivo metabolism is rapid, the biological half-life period is shorter, the in-vivo clearing time is obviously shorter than that of an antibody molecular probe, and the safety is higher. In conclusion, the two molecular probes can dynamically monitor the change of the level of carbonic anhydrase IX in tumor cells in real time through PET imaging, and have great application prospects in diagnosis of positive tumors of carbonic anhydrase IX.

The invention relates to the technical field of molecular probes, and particularly discloses a molecular probe of a targeted tyrosine kinase receptor as well as a preparation method and application of the molecular probe, the molecular probe comprises radioisotope, targeted polypeptide and a chelating group, the targeted polypeptide specifically targets the tyrosine kinase receptor, the chelating group is connected with the targeted polypeptide to form a targeted precursor, and the chelating group is connected with the targeted polypeptide to form the targeted precursor. The radioactive isotope labeled precursor forms a molecular probe, and the sequence of the targeted polypeptide is shown as any one of SEQ ID No.1-8. The targeting polypeptide has good targeting property on a tyrosine kinase receptor coded by an RET gene, can realize specific high uptake in a cell line of NEPC, has relatively good biological safety, can realize accurate imaging aiming at NEPC, and clearly and durably visualizes NEPC tumors in PET imaging; meanwhile, the molecular probe can effectively delay the growth capacity of NEPC, can provide a new treatment choice for NEPC patients, and has good clinical transformation potential.

Alzheimer's disease, the most common cause of dementia in older individuals, is a debilitating neurodegenerative disease for which there is currently no cure. In the past, AD could only be definitively diagnosed by brain biopsy or upon autopsy after a patient died. These methods, which demonstrate the presence of the characteristic plaque and tangle lesions in the brain, are still considered the gold standard for the pathological diagnoses of AD. However, in the clinical setting brain biopsy is rarely performed and diagnosis depends on a battery of neurological, psychometric and biochemical tests, including the measurement of biochemical markers such as the ApoE and tau proteins or the beta-amyloid peptide in cerebrospinal fluid and blood. The present invention discloses and describes panels of makers that are differentially expressed in the disease state relative to their expression in the normal state and, in particular, identifies and describes panels of makers associated with neurocognitive disorders. Such biomarker panel might have considerable value in triaging patients with early memory disorders to yet more specific but more invasive and costly approaches such as molecular markers in CSF and on PET imaging in clinical trials and possibly in clinical practice.

The invention relates to a PD-L1 targeted biphenyl radioactive tracer and application thereof, and belongs to the technical field of PET imaging. The invention provides a series of PD-L1 targeted biphenyl radioactive tracers which comprise [18F] LG-2, [18F] LG-3, [18F] LG-13, [18F] LG-14, [18F] LG-15 and the like, the series of biphenyl radioactive tracers have good in-vitro stability, can be specifically combined with PD-L1, and are relatively good in targeting specificity, and therefore, the series of biphenyl radioactive tracers can be applied to the field of radioactive tracers. The series of biphenyl radioactive tracers can noninvasively, accurately, dynamically and systemically monitor the expression level and change of PD-L1 in tumors from the molecular level in real time through PET imaging, and then the curative effect of PD-1 / PD-L1 immunotherapy on tumor patients is effectively evaluated.

The invention discloses an early evaluation method, device and system for Alzheimer's disease. The method comprises the following steps: detecting whether a user completes a preset short-term task or not; when the user completes the preset short-term task, acquiring physiological data of the user; inputting the physiological data into an evaluation model to obtain a risk score, the evaluation model being an Alzheimer's disease early evaluation model; and generating an assessment report according to the risk score. According to the method, when the user completes the preset short-term task, the physiological data of the user are collected and input into the Alzheimer's disease early assessment model to obtain the risk score, so that the assessment report is obtained, the assessment report can be obtained without lumbar puncture, PET imaging detection and high-resolution MRI detection of the user, and the user experience is improved. The compliance is improved; the detection cost is reduced; and the detection timeliness is improved.

The invention discloses a human-derived hysteromyoma targeting peptide and application thereof, the sequence of the targeting peptide is selected from SEQ ID NO: 1 to SEQ ID NO: 5, and the SEQ ID NO: 1 (VN12) is the most preferable. The fusion protein is obtained by screening through a phage display technology, and has high hysteromyoma targeting specificity and low immunogenicity. The targeting peptide can be coupled with nuclide or fluorescent dye, and is used for accurate PET imaging, fluorescent diagnosis and intraoperative navigation of hysteromyoma. Experiments prove that the molecular marker is specifically enriched in tumor tissues (the tumor / muscle ratio is 60), the biological safety is good, the problems of insufficient diagnosis sensitivity and large treatment wound in the prior art are solved, and the molecular marker has a great application prospect in diagnosis and treatment of hysteromyoma.

The invention provides an FAPI trimer compound, a preparation method of the FAPI trimer compound, a PET developer based on the FAPI trimer compound and a preparation method of the developer. Amphipathic polyethylene glycol chains and trimeric structures in molecules of the FAPI trimer compound can improve in-vivo dynamic characteristics of the compound, and the in-vivo dynamic characteristics of the compound can be improved. The residence time in the tumor is prolonged; the PET imaging agent based on the FAPI trimer compound can improve the uptake and imaging effects of the PET imaging agent in tumors, and has good application prospects in PET imaging, preparation of drugs for diagnosing FAP-q expressed tumors and drugs for marking therapeutic nuclide (177Lu or 90Y) to treat the FAP-q expressed tumors in the future.

The invention discloses a PET (positron emission tomography) imaging agent, a precursor and a probe for targeting an EphA2 receptor as well as a preparation method and application of the PET imaging agent, the precursor and the probe, and a radioactive probe which is formed by labeling a chelating agent (such as DOTA and NOTA) and a radionuclide (such as 68Ga) by taking bicyclic peptide as a targeting group is specifically combined with the EphA2 receptor highly expressed on the surface of a tumor cell. According to the invention, a conformation limitation strategy is adopted for transforming the peptide probe targeting EphA2 for the first time, the bicyclic peptide radioactive probe with excellent targeting performance and in-vivo imaging effect is obtained, the tumor uptake value is high, and tumor and non-tumor imaging is clear; and successful imaging in a fibrosarcoma model. According to the EphA2 receptor-targeted PET imaging agent provided by the invention, the precursor, namely the probe, has the advantages of simplicity in preparation, good targeting property, excellent imaging effect and the like, can be used for PET imaging diagnosis, prognosis evaluation and targeted therapy guidance of EphA2 positive tumors, and has good clinical value.

There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.

The present application provides a preparation method for a liquid composition comprising Compound I and its use in myocardial perfusion PET imaging. The method comprising the following steps: purifying a crude product comprising the compound I by using high-performance liquid chromatography, wherein a mobile phase used in the high-performance liquid chromatography purification step comprises ethanol and water. By optimizing process parameters and technological process, the method of the present application can be applied to large-scale activity production and meet automation needs. An obtained myocardial perfusion PET imaging agent of this application has high radiochemical purity, high activity concentration, good product stability, and high and stable yield or productivity.

A method for estimating noise equivalent counts includes one or more times during a scan of an object with a positron emission tomography (PET) scanner, wherein a plurality of coincidence events are detected by a detector array of the PET scanner, performing the following actions. The actions include obtaining a total of the plurality of coincidence events, estimating random coincidence events, and estimating scatter coincidence events. The actions include estimating true coincidence events based on the total of the plurality of coincidence events, the estimated random coincidence events, and the estimated scatter coincidence events. The actions include determining a scatter fraction based on the estimated scatter events and true coincidence events. The actions include estimating the noise equivalent counts based at least on the scatter fraction, the total of the plurality of coincidence events, the estimated true coincidence events, the estimated scatter coincidence events, and the estimated random coincidence events.

The present invention provides a method for preparing and using a Trop2-specific integrated diagnostic and therapeutic molecular imaging probe. The Trop2-specific molecular imaging probe, constructed based on the Trop2-specific nanoantibodies WWD98 and WWD328, can be used for immuno-PET imaging. Immuno-PET imaging using the probe can non-invasively display Trop2 expression within tumors, achieving non-invasive visualization of human Trop2 molecular expression. This provides a better method for diagnosing and monitoring Trop2-positive solid tumors and can further enable non-invasive diagnosis of various tumors, such as pancreatic cancer and gastric cancer. The probe of the present invention has the advantages of a simple preparation process, low cost, high specificity, high stability, short imaging cycle, low radiation dose, and ease of clinical translation.

The present invention provides a radiolabeled compound targeting cannabinoid receptor type 2 labeled with the radionuclide 18F. The present invention also provides a process for the preparation of said compound and its use as a positron emission tomography (PET) imaging agent.

The invention discloses a polypeptide PET (Polyethylene Terephthalate) developer targeting FGFR1 (Fibroblast Growth Factor Receptor). The structure of the polypeptide PET developer targeting FGFR1 is shown as a formula (1), r1 is a bifunctional chelating group and is selected from at least one of a formula (2) or a formula (3); Mn < + > is marked radionuclide chelated with R1; the radionuclide Mn < + > is selected from at least one of [Al18F] < 2 + >, < 68 > Ga < 3 + >, < 64 > Cu < 2 + > and < 177 > Lu < 3 + >. The structure of the FGFR1-targeted polypeptide PET imaging agent comprises polypeptide, a bifunctional chelating agent and radionuclide, the preparation method is simple and rapid, the yield is high, the PET imaging agent is good in stability, high in water solubility and high in in-vivo blood removal speed, the PET imaging agent is mainly metabolized by the kidney and can be specifically taken by a high-expression tumor site of the FGFR1, and the PET imaging agent can be widely applied to biological function imaging.

The application belongs to the technical field of biological medicine, and discloses a synthesis method of aryl F-18 labeled sulfuryl chloride and application of the aryl F-18 labeled sulfuryl chloride in amine compound labeling. The method takes thiophenol derivative as a labeling precursor, obtains F-18 labeled thiophenol intermediate through photocatalytic aryl F-18 fluorination reaction, and then obtains aryl F-18 labeled sulfuryl chloride through N-chlorosuccinimide oxidation chlorination. The obtained aryl F-18 labeled sulfuryl chloride (4-[ 18 F] fluorobenzenesulfonyl chloride) can occur sulfurylization reaction with various amine compounds at room temperature, and the radiochemical conversion rate is as high as 98%. The application is successfully applied to novel synthesis of AMPA receptor PET imaging agent[ 18 F]2 (the conversion rate is 96%, which is much higher than 13% reported in the literature). The application has the advantages of mild reaction condition, high conversion rate and wide substrate application range, and provides an efficient method for innovative preparation of F-18 labeled PET probes.

A compound or pharmaceutically acceptable salt thereof has at least one bis-phosphonate or bisphosphonate ester group, and a positron emitting radionuclide Po. The positron emitting radionuclide Po is attached to the at least one bisphosphonate or bisphosphonate ester group. The compound may be useful in a method of diagnosis of amyloidosis, such as cardiac amyloidosis.

The invention discloses a PET imaging device for multi-radiation-field particle therapy, PET equipment and a therapy system. The PET imaging device comprises: an identification unit configured to identify one or more time intervals of each radiation field according to time distribution characteristics of collected single event data, each time interval corresponding to a particle beam delivery state; the coincidence processing unit is configured to perform coincidence processing on the single event data to generate coincidence event data; and the reconstruction unit is configured to perform image reconstruction on the coincidence event data in the identified time interval of each radiation field to obtain a reconstructed image corresponding to each radiation field. Through intelligent identification of time distribution characteristics and a partition reconstruction strategy, the problem of serious aliasing of PET signals in a multi-radiation-field delivery mode is solved, and accurate extraction of independent dose distribution of each radiation field and image reconstruction are realized.

Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and / or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and / or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

The invention provides a pAKT-targeted small molecule compound, a PET molecular probe precursor, a PET molecular probe and a preparation method and application of the PET molecular probe. The PET molecular probe disclosed by the invention is a radioactive probe which is modified on the basis of a chemical structure of a medicine Caprivastib (AZD5363) and is marked by 68Ga and is targeted to pAKT. According to the probe, structural modification is carried out on Capivasertib, the area, combined with PKA, of Capivasertib is changed, precursor molecules combined with pAKT in a high-specificity mode are obtained, and the precursor molecules are further researched, developed and modified into the radioactive probe targeting pAKT capable of being used for PET imaging. The probe has relatively low abdominal nonspecific uptake, can effectively distinguish tumors with high expression and low expression of pAKT in vivo, and can predict and early evaluate the response condition of the tumors to a PI3K / AKT pathway related inhibitor. Therefore, the probe has a very strong clinical application prospect, on one hand, the probe can be used for analyzing the expression quantity of pAKT in tumor tissues; on the other hand, the probe can also be used for predicting and early evaluating the effect of the PI3K / AKT pathway related inhibitor in anti-tumor treatment.

The application discloses a polypeptide PET molecular probe for targeting breast cancer and a preparation method and application thereof. The polypeptide PET molecular probe for targeting breast cancer is obtained by labeling an AR polypeptide modified by a bifunctional chelating agent with a positron emitting radionuclide, and has the advantages of simple synthesis, small molecular weight, high specificity, no immunogenicity and good biological safety. In addition, the polypeptide PET molecular probe has high radiochemical performance and in-vivo and in-vitro stability, can better realize breast cancer targeted PET imaging compared with current commonly used imaging agents, can be used for preparing an imaging agent for breast cancer diagnosis, and is helpful for clinical diagnosis of breast cancer.

The invention belongs to the technical field of biological medicine, and particularly discloses a compound targeting MAT2A and application thereof. The structure of the compound is shown as a formula I in the specification. The compound designed by the invention can be used as a PET imaging probe to realize early accurate diagnosis and staging of MAT2A high-expression tumors and meet the whole-process clinical requirements of'diagnosis-curative effect evaluation 'of solid tumors.

The invention discloses an early evaluation method, device and system for Alzheimer's disease. The method comprises the following steps: acquiring magnetic resonance imaging data and physiological data of a user; inputting the magnetic resonance imaging data and the physiological data into a cross-modal feature fusion model to obtain fusion features; inputting the fusion features into an expert model to obtain a prediction result; and generating an evaluation report according to the prediction result. According to the method, the magnetic resonance imaging data and the physiological data are processed through the cross-modal feature fusion model, so that the high-level fusion features are obtained, then the expert model is used for processing the fusion features, so that the prediction result is obtained, the evaluation report is obtained, a user can obtain the evaluation report without lumbar puncture and PET imaging detection, and the user experience is improved. The compliance is improved; and the detection cost is reduced.

The present invention provides a PET attenuation correction method and system for a five-modality integrated brain imaging device, relating to the field of brain imaging technology. The method comprises: generating a first attenuation coefficient map for a fixed-position hardware component; generating a second attenuation coefficient map for the optode and optical fiber of a non-fixed-position functional near-infrared spectrometer; superimposing the first attenuation coefficient map with the second attenuation coefficient map to generate a third attenuation coefficient map of the PET image under scanning conditions; and performing registration and attenuation correction on the third attenuation coefficient map to obtain an attenuation-corrected PET image. The present invention can more accurately obtain an attenuation template under each actual acquisition environment, and maximizes the correction of the effects of hardware components in the imaging field of view on the attenuation and scattering of gamma photons in PET imaging.

A method for determining a convolution kernel for an iterative statistical algorithm based on a continuous-to-continuous data model. The method is used for image reconstruction from radiation measurements obtained in emission tomography, specifically in a Time-of-Flight Positron Emission Tomography (TOF PET) scanner. The presented method is a non-list-mode solution that reduces the computational complexity of the reconstruction problem, improves the resolution of reconstructed images, reduces the radiation dose absorbed by patients during TOF PET examinations, and / or shortens the measurement acquisition time without significantly compromising the quality of the diagnostic images. Notably, the quality of the functional images remains at the same level. These improvements are achieved by designing the convolution kernel to account for the statistical properties of the measurement signals registered during the TOF PET scanner's acquisition process.

According to the GLP1R targeted radioactive probe, the preparation method and the application, the GLP1R targeted radioactive probe can be specifically combined with GLP1R, has the good in-vivo biological metabolism property, does not cause blood glucose reduction after being injected and is a potential glucagon-like peptide-1 receptor PET imaging probe. The GLP1R targeted radioactive probe is [68Ga] Ga-NOTA-1D32, [68Ga] Ga-NOTA-1D36, or [68Ga] Ga-NOTA-1D39, and the GLP1R targeted radioactive probe is a GLP1R targeted radioactive probe, or a GLP1R targeted radioactive probe, or a GLP1R targeted radioactive probe.

The application discloses a method for constructing fluorine-containing compounds by decarboxylation of alkyl carboxylic acid catalyzed by ketone compounds. The method uses alkyl carboxylic acid with a structure as shown in formula as a reaction raw material, and performs reaction under the joint action of ketone compounds, fluorine-containing reagents and alkali to obtain fluorides shown in formula (1) and formula (2), wherein R 1 are respectively and independently selected from hydrogen, a heterocyclic ring, substituted or unsubstituted aryl, and substituted or unsubstituted hydrocarbyl; R 2 are respectively and independently selected from hydrogen, a heterocyclic ring, substituted or unsubstituted aryl, and substituted or unsubstituted hydrocarbyl; R 3 are respectively and independently selected from hydrogen, a heterocyclic ring, substituted or unsubstituted aryl, and substituted or unsubstituted hydrocarbyl. The reaction method has the advantages of low cost, mild conditions, high reaction efficiency, high yield and high selectivity, and the like. The ketone compounds are used to replace traditional metal catalysts, which can not only provide a fluorine-containing compound library with various structures for candidate drug screening, but also can be applied to positron emission tomography imaging.

Provided herein are radiolabelled anti-MET antibodies and MET x MET bispecific antibodies and their use in immune PET imaging. Including methods of detecting the presence of MET protein in a subject or sample and methods of monitoring the efficacy of treatment of Met-expressing tumors.

The present application relates to the field of biological medicine, and provide a kind of targeting PSMA dimer compound and its derivative and application, the structure general formula of the dimer compound is as shown in formula (I).The dimer compound and its derivative of the present application have very high affinity and targeting to PSMA, after being labeled with suitable radionuclide, can be used as nuclear medicine molecular probe, to realize early diagnosis, staging and treatment of prostate cancer, 68 Ga]diPSMA-1-DOTA showed good tumor uptake in PET imaging of tumor mice.Therefore, this kind of radioactive complex has good clinical application prospect in tumor imaging targeting PSMA (especially PET imaging), and lays an important foundation for the radiotherapy application of [ 177 Lu]diPSMA-1-DOTA and [ 225 Ac]diPSMA-1-DOTA.